ANNUAL REPORT 2007 | 2008 - Gimv

PamGene
www.pamgene.com
PamGene, a Ditch biotech spin-off of Organon Technika, is
developing test chips based on microarray technology, which
is one of the most important analysis technologies in molecular
biology research. The PamChip has a much faster analysis time
than the better known DNA chips: a few minutes in place of
hours. As well as DNA analysis PamGene is also using the same
technology to examine how cells react to the administration of
certain medicines. This would enable medicines with less sideeffects
to be brought more effi ciently onto the market. Japanese
company Olympus and Belgian company Innogenetics have
licensed in PamGene’s platform technology for diagnostic applications.
PamGene has been in the Gimv portfolio since 2000.
Plexxikon
www.plexxikon.com
American company Plexxikon is a leading player in researching
and developing new drugs for handling cardiovascular and
metabolic disorders, infl ammations and cancers. The research
is based on its proprietary technology platform that uses structural
screening and analysis in as early a stage as possible
in developing drugs. Plexxikon has signed partnerships with
Servier, Wyeth Pharmaceuticals and Genentech Inc. In 2006
Plexxikon concluded a cooperation agreement with Roche to
develop a cancer drug. Gimv has been supporting Plexxikon
since 2002.
Xanthus Pharmaceuticals
www.xanthus.com
Xanthus Pharmaceuticals was set up in Massachusetts, USA,
in 2001. It researches, develops and markets new therapies
to combat cancer and auto-immune disorders. The broad
portfolio of licensed-in products, including Xanafi de and Oral
Fludarabine, is spread over various stages of research. Gimv
entered Xanthus in 2003.
| 53